First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers

Author： Saito Kaku   Nagashima Hirotaka   Noguchi Kazuharu   Yoshisue Kunihiro   Yokogawa Tatsushi   Matsushima Eiji   Tahara Takeshi   Takagi Shigeru  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.3, 2014-03, pp. : 577-583

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

By Camidge D.   Smethurst Dominic   Growcott Jim   Barrass Nigel   Foster John   Febbraro Salvatore   Swaisland Helen   Hughes Andrew  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 391-398

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite

Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1)

By Massaccesi Mariangela   Ferro Marica   Cilla Savino   Balducci Mario   Deodato Francesco   Macchia Gabriella   Valentini Vincenzo   Morganti Alessio  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 784-791

Springer Publishing Company

Access to resources Recommend Favorite